| Multiparametric approach for the evaluation of lipid nanoparticles for siRNA delivery CA Alabi, KT Love, G Sahay, H Yin, KM Luly, R Langer, DG Anderson Proceedings of the National Academy of Sciences 110 (32), 12881-12886, 2013 | 176 | 2013 |
| Nanoparticle designs for delivery of nucleic acid therapeutics as brain cancer therapies J Karlsson, KM Luly, SY Tzeng, JJ Green Advanced drug delivery reviews 179, 113999, 2021 | 38 | 2021 |
| Photocrosslinked bioreducible polymeric nanoparticles for enhanced systemic siRNA delivery as cancer therapy J Karlsson, SY Tzeng, S Hemmati, KM Luly, O Choi, Y Rui, DR Wilson, ... Advanced functional materials 31 (17), 2009768, 2021 | 33 | 2021 |
| Safety considerations for nanoparticle gene delivery in pediatric brain tumors KM Luly, J Choi, Y Rui, JJ Green, EM Jackson Nanomedicine 15 (18), 1805-1815, 2020 | 12 | 2020 |
| Non-cell-adhesive substrates for printing of arrayed biomaterials EA Appel, BL Larson, KM Luly, JD Kim, R Langer Advanced healthcare materials 4 (4), 501, 2015 | 10 | 2015 |
| Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications J Yang, KM Luly, JJ Green Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 15 (2 …, 2023 | 9 | 2023 |
| Poly (beta-amino ester) s as high-yield transfection reagents for recombinant protein production KM Luly, H Yang, SJ Lee, W Wang, SD Ludwig, HE Tarbox, DR Wilson, ... International journal of nanomedicine 17, 4469, 2022 | 6 | 2022 |
| Non-viral gene delivery to hepatocellular carcinoma via intra-arterial injection HJ Vaughan, CG Zamboni, KM Luly, L Li, KL Gabrielson, LF Hassan, ... International journal of nanomedicine, 2525-2537, 2023 | 2 | 2023 |
| Biodegradable Polyester Nanoparticle Vaccines Deliver Self‐Amplifying mRNA in Mice at Low Doses DR Wilson, SY Tzeng, Y Rui, SY Neshat, MJ Conge, KM Luly, E Wang, ... Advanced Therapeutics 6 (5), 2200219, 2023 | 2 | 2023 |
| 222 Genetic reprogramming of Merkel cell carcinoma and melanoma leads to increased MHC-I expression and antitumor immune activation in vitro and in vivo K Luly, J Green, S Tzeng, J Sunshine Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 2 | 2021 |
| Lenalidomide in combination with the activin receptor type ii murine Fc protein RAP-011: preclinical rationale for a novel anti-myeloma strategy S Vallet, K Patel, D Cirstea, K Luly, S Pozzi, L Santo, H Eda, J Seehra, ... Blood 116 (21), 4075, 2010 | 2 | 2010 |
| CYC065, A potent derivative of seliciclib is active in multiple myeloma in preclinical studies S Pozzi, D Cirstea, L Santo, DM Nabikejje, K Patel, KM Luly, ... Blood, The Journal of the American Society of Hematology 116 (21), 2999-2999, 2010 | 2 | 2010 |
| Abstract B37: development of inhibitors of the activated form of KRAS G12C ML Stewart, NR Perl, SJ Lee, L Xue, M Zhou, J Simon, KM Luly, S Grigoriu, ... Molecular Cancer Research 18 (5_Supplement), B37-B37, 2020 | 1 | 2020 |
| Suprachoroidal gene transfer with nonviral nanoparticles in large animal eyes J Shen, R Lima e Silva, M Zhang, KM Luly, SF Hackett, SY Tzeng, ... Science Advances 10 (10), eadl3576, 2024 | | 2024 |
| Biomaterial-Mediated Genetic Reprogramming of Merkel Cell Carcinoma and Melanoma Leads to Targeted Cancer Cell Killing In Vitro and In Vivo KM Luly, JJ Green, JC Sunshine, SY Tzeng ACS Biomaterials Science & Engineering 9 (11), 6438-6450, 2023 | | 2023 |
| 1181 Delivery of costimulatory molecules and immunostimulatory cytokines leads to targeted and systemic immune activation against melanoma in vivo KM Luly, JJ Green, JC Sunshine, SY Tzeng Journal of Investigative Dermatology 143 (5), S203, 2023 | | 2023 |
| 801 Novel nanoparticles mediate efficient siRNA/mRNA co-delivery to melanoma KM Luly, EE Rocher, JJ Green, SY Tzeng, JC Sunshine Journal of Investigative Dermatology 143 (5), S138, 2023 | | 2023 |
| 003 In vitro genetic reprogramming increases MHC-I expression and ameliorates resistance to an antitumor immune response in Merkel cell carcinoma KM Luly, JJ Green, SY Tzeng, JC Sunshine Journal of Investigative Dermatology 141 (5), S1, 2021 | | 2021 |
| Development of inhibitors of the activated form of KRAS G12C. ML Stewart, NR Perl, SJ Lee, L Xue, M Zhou, J Simon, KM Luly, S Grigoriu, ... MOLECULAR CANCER RESEARCH 18 (5), 70-70, 2020 | | 2020 |
| Development of inhibitors of the activated form of KRAS G12C R Pollock, M Stewart, N Perl, SJ Lee, L Xue, M Zhou, J Simon, K Luly, ... EUROPEAN JOURNAL OF CANCER 103, E52-E52, 2018 | | 2018 |
